Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel V Catenacci

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
JAMA Network Open|November 30, 2021
Evaluating the Value of a New Prediction Model for Gastric CancerJesse A Berlin, Daniel V Catenacci
Future Oncology (London, England)|November 3, 2017
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinomaSmita S Joshi, Steven B Maron, Daniel V Catenacci
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2017
It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal AdenocarcinomaElena Elimova, Yelena Y Janjigian, Mary Mulcahy, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?Daniel Lin, Uqba Khan, Thorsten O Goetze, et al.
Surgery|October 10, 2018
Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trialFadi S Dahdaleh, Scott K Sherman, Elizabeth C Poli, et al.
Pancreas|September 22, 2015
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic AdenocarcinomaAndrew H Ko, Noelle LoConte, Margaret A Tempero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2020
Treatment of Locally Advanced Esophageal Carcinoma: ASCO GuidelineManish A Shah, Erin B Kennedy, Daniel V Catenacci, et al.
The Oncologist|July 21, 2021
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction AdenocarcinomaDaniel V Catenacci, Joseph Chao, Kei Muro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2019
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid TumorsGerald S Falchook, Razelle Kurzrock, Hesham M Amin, et al.
The Oncologist|May 2, 2019
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for TherapyAparna R Parikh, Yuting He, Ted S Hong, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
JAMA Network Open|November 30, 2021
Evaluating the Value of a New Prediction Model for Gastric CancerJesse A Berlin, Daniel V Catenacci
Future Oncology (London, England)|November 3, 2017
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinomaSmita S Joshi, Steven B Maron, Daniel V Catenacci
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2017
It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal AdenocarcinomaElena Elimova, Yelena Y Janjigian, Mary Mulcahy, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?Daniel Lin, Uqba Khan, Thorsten O Goetze, et al.
Surgery|October 10, 2018
Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trialFadi S Dahdaleh, Scott K Sherman, Elizabeth C Poli, et al.
Pancreas|September 22, 2015
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic AdenocarcinomaAndrew H Ko, Noelle LoConte, Margaret A Tempero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2020
Treatment of Locally Advanced Esophageal Carcinoma: ASCO GuidelineManish A Shah, Erin B Kennedy, Daniel V Catenacci, et al.
The Oncologist|July 21, 2021
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction AdenocarcinomaDaniel V Catenacci, Joseph Chao, Kei Muro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2019
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid TumorsGerald S Falchook, Razelle Kurzrock, Hesham M Amin, et al.
The Oncologist|May 2, 2019
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for TherapyAparna R Parikh, Yuting He, Ted S Hong, et al.
Pageof 2